Drug-Coated Balloon for In-Stent Restenosis: First Experience

Drug-Coated Balloon for In-Stent Restenosis: First Experience

0:00

Bruno Scheller Bruno Scheller, Universitatsklinikum des Saarlandes, Homburg Saar A future option for treating in-stent restenosis is the idea of coating a balloon with an anti-proliferative drug and i

Bruno Scheller

Bruno Scheller

Bruno Scheller, Universitatsklinikum des Saarlandes, Homburg SaarA future option for treating in-stent restenosis is the idea of coating a balloon with an anti-proliferative drug and inflating it inside the newly-occluded stent. At the ESC Congress,Bruno Schellerfrom the University of Saarland presented the first study of such a device in humans. He told Audio Medica about it.

Click here for all the interviews from ESC 2005

Related Episodes

TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?

TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?

Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GREGG STONE, Columbia University, New York New light has been thrown on the u

Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI

Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI

Laura Mauri Raymond Gibbons REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LAURA MAURI, Brigham and Woman’s Hospit

Patients with High Restenosis Risk Benefit More from Drug Eluting Stents

Patients with High Restenosis Risk Benefit More from Drug Eluting Stents

Raul Moreno REFERENCE: Abstract 3103, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria RAUL MORENO, University Hospital La Paz, Madrid Results from a large meta analysis s